Group 1 - Two companies, Xiantong Pharmaceutical and Huaxida, have submitted applications for listing on the Hong Kong Stock Exchange after delisting from the New Third Board, indicating a new wave of companies seeking to transition to the Hong Kong market [1][3] - Xiantong Pharmaceutical is a leader in the nuclear medicine sector, backed by significant capital from Kweichow Moutai Group's Moutai Jinshi Fund, enhancing its strategic positioning for the Hong Kong listing [3] - Huaxida focuses on Android TV smart terminal devices and has established a broad global distribution network, with Tencent holding a 3.13% stake, marking its second attempt at capital raising after failing to list on the Beijing Stock Exchange [3] Group 2 - In 2023, over 10 companies have successfully transitioned from the New Third Board to the Hong Kong Stock Exchange, with an additional 23 companies processing transfer applications, reflecting a trend of companies seeking to capitalize on the Hong Kong market [3][4] - The influx of New Third Board companies to Hong Kong signals a growing demand for larger, more international financing platforms, as the Hong Kong market offers greater liquidity and serves as a strategic launchpad for global operations [4] - The Hong Kong capital market's internationalization, flexible listing regulations, and diverse investor base make it particularly attractive for new economy sectors like biomedicine and technology, providing growth-stage companies with essential financing opportunities [4]